Harrow Q4 2021 Earnings Report
Key Takeaways
Harrow Health reported record revenues for the fourth quarter of 2021, marking the sixth consecutive quarter of record performance. The company also achieved a gross margin of 75% during the quarter.
Reported sixth consecutive quarter of record revenues.
Gross margin improved to 75% for the fourth quarter.
Filed first New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).
Began to realize high-margin revenues from recently acquired FDA-approved branded products.
Harrow
Harrow
Forward Guidance
2022 is shaping up to be a ‘break-out’ year for Harrow Health. In the second quarter of 2022, the company is expecting top-line readouts on clinical studies from two of their non-controlling equity positions, followed in mid-October by a determination by the FDA on their NDA for AMP-100.
Positive Outlook
- Expecting top-line readouts on clinical studies from two of our non-controlling equity positions in the second quarter of 2022.
- FDA determination expected in mid-October on NDA for AMP-100.
- Potential commercial launch a few months after FDA approval.
- Focus on growing core ophthalmic pharmaceuticals business.
- Launching new ophthalmic products internally developed.